{
    "2018-04-18": [
        [
            {
                "time": "2018-04-17",
                "original_text": "Xultophy® approved in Canada for the treatment of adults with type 2 diabetes",
                "features": {
                    "keywords": [
                        "Xultophy",
                        "approved",
                        "Canada",
                        "type 2 diabetes"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Analysts’ Recommendations for Novartis on April 17",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommendations",
                        "Novartis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-17",
                "original_text": "Novartis’s 1Q18 Estimates: Expectations for Alcon",
                "features": {
                    "keywords": [
                        "Novartis",
                        "1Q18",
                        "Estimates",
                        "Alcon"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "ophthalmology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}